Perth Blood Institute are partnering with Gamma Diagnostics to study the role that Gamma Prime Fibrinogen (GPF) plays in various inflammatory disease states. The Long COVID Syndrome Study (GPF LoCov Study) will be investigating if a certain coagulation factor, Gamma Prime Fibrinogen (GPF) is elevated in patients with acute and long COVID. As GPF is also an inflammatory marker associated with cardiovascular disease (Appiah et al. 2015), a secondary aim of the study is to see if there is a correlation between GPF and other coagulation, inflammatory and endothelial markers.